関連する実験動画
Updated: May 2, 2026

07:36
Angiogenesis in the Ischemic Rat Lung
Published on: February 8, 2013
15.3K
高コレステロール血症は,後肢のイシュケミアの反応として血管新生を阻害する:酸化窒素に依存するメカニズム
1Cardiovascular Research Institute and Department of Internal Medicine III, Kurume University School of Medicine, Kurume, Japan.
Circulation
|November 18, 2000
まとめ
高コレステロールは,マウスの肢体イシュケミアの後の血管形成を損なう. 口服によるL-アルギニンサプリメントは,酸化窒素 (NO) の活性性を高めることで血管新生を改善しました.
科学分野:
- 心血管生物学 心血管生物学
- 血管生物学 血管生物学
- 再生医学は,再生医療である.
背景:
- 内皮から派生した酸化窒素 (EDNO) は血管新生を調節する.
- 高コレステロール血症 (HC) は,EDNOの放出を阻害する.
- HCは,EDNOの減少を介して,血管新生ポストイシェミアを阻害する可能性があります.
研究 の 目的:
- HCがEDNOを減少させることで,イシュケミア誘発の血管新生を阻害するかどうかを調査する.
- L-アルギニンサプリメントがHCに関連する血管新生障害を予防できるかどうかを判断する.
主な方法:
- ネズミは,標準的,高コレステロール (HC),またはL-アルギニンを含むHCの食事を与えられました.
- 片側後肢イシュケミアは外科的に誘発された.
- 血流,血管撮影,毛細血管密度,および組織 NO ((x) /cGMP レベルが分析されました.
主要な成果:
- HCは,血流,血管新生,および血小管の密度を低下させました.
- HCは,組織中の酸化窒素 (NO) の生物利用性の低下と関連していました.
- L-アルギニンのサプリメントは,HCラットの血流と血管新生を著しく改善しました.
結論:
- ダイエットによる高コレステロール血症は,後肢イシュケミアの後の血管新生を弱める.
- NOの生物学的利用性の低下は,HCにおける血管新生障害の潜在的なメカニズムである.
- L-アルギニンのサプリメントはHCマウスの血管新生を効果的に回復させた.
関連する概念動画
Mechanism of Angiogenesis
6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K
Regulation of Angiogenesis and Blood Supply
2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Nitric Oxide Signaling Pathway
5.3K
Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
Cholesterol: Significance and Regulation
2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.1K
Angina IV: Management
493
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
493
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

